Search - tctmd.com

Displaying 41 - 55 of 55

Sort: Relevancy | Date

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2022

Shelley Wood

February 28, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

Presentation THT 2022

EMPULSE: The Use of SGLT2 Inhibitors in Acute Decompensated Heart Failure

Presenter: Piotr Ponikowski

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presenter: Stefan Anker

February 01, 2022

Presentation THT 2022

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Alanna Morris

February 01, 2022

Presentation THT 2022

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

Presenter: Piotr Ponikowski

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors in HFrEF and HFpEF

Presenter: Stefan Anker

February 01, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Todd Neale

January 26, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

Advertisement

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

TCTMD’s Top 10 Most Popular Stories for February 2022

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

EMPULSE: The Use of SGLT2 Inhibitors in Acute Decompensated Heart Failure

SGLT2 Inhibitors: What the Clinician Should Know

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

SGLT2 Inhibitors in HFrEF and HFpEF

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content